RxDoctor Payments Data

Adam Lucas, MD

Cardiovascular Disease · Hamilton, NJNPI 1083011605

Payments from drug & device makers

$1,269in general payments, 2019–2025

Across 61 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$610
  • Novo Nordisk$176
  • Amgen$67
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$64
  • Angiodynamics, Inc.$47
  • Bayer$38
  • plus $268 from 13 others

What the payments were for

  • Food & beverage$1,269100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,269 in reported general payments places this provider in the 30th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$497,638
Medicare patients
1,712
Services billed
4,751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban124$158,456
XareltoRivaroxaban33$40,823
EntrestoSacubitril/Valsartan26$32,215
FarxigaDapagliflozin Propanediol16$16,844
BrilintaTicagrelor15$16,553
Repatha SureclickEvolocumab12$13,154
JardianceEmpagliflozin17$13,027
Rosuvastatin Calcium244$4,826
Metoprolol Succinate159$2,343
Atorvastatin Calcium157$1,334
Amlodipine Besylate144$1,181
Irbesartan-HydrochlorothiazideIrbesartan/Hydrochlorothiazide46$1,016
Ezetimibe46$958
Valsartan43$904
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide16$902

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$158,456124 claims
Johnson & JohnsonXarelto$17$40,82333 claims
AstraZenecaFarxiga, Brilinta$14$33,39731 claims
NovartisEntresto$19$32,21526 claims
Boehringer IngelheimJardiance$31$13,02717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Hamilton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →